Printer Friendly

INAMED REPORTS THIRD QUARTER RESULTS

 INAMED REPORTS THIRD QUARTER RESULTS
 SANTA BARBARA, Calif., Nov. 20 /PRNewswire/ -- INAMED Corporation


(NASDAQ: IMDC; PSE: INA), headquartered here, today reported record third quarter and nine month sales of $9,242,869 and $31,182,890 for periods ended Sept. 30, 1991. This compares to sales of $8,778,799 and $26,621,837 for the same reporting periods in 1990.
 Profits for the third quarter 1991 were $90,986, or $0.01 per share, compared to $320,504, or $0.04 per share, in 1990. Profits for the nine months ended Sept. 30, 1990, were $954,489, or $.12 per share, compared to $976,540, or $0.12 per share, for the same period in 1990.
 Although the company continues to report sales increases, both sales and profits in the third quarter were adversely affected by regulatory actions taken by the Food and Drug Administration (FDA) relating to gel-filled mammary prostheses. In July, the FDA issued a mandate that INAMED's wholly owned subsidiary, McGhan Medical Corporation, use its best efforts to retrieve gel-filled mammary prostheses not covered by the Pre-Market Approval (PMA) application filed in the same month. In compliance with this mandate, during the third quarter, McGhan Medical initiated the required retrieval of the non-PMA products.
 "The company incurred significant expense in adhering to the FDA's request to retrieve non-PMA'd products from the market," said Chairman Donald K. McGhan. "However, during the third quarter we were successful in retrieving approximately 75 percent of the subject products which the company elected to expense in the third quarter."
 Last week an FDA advisory panel voted unanimously to recommend that the company's silicone gel-filled breast implants, which are covered by a PMA application filed in July 1991, remain on the market while more safety data is gathered and evaluated by the agency. A final decision on the approval of the PMA application will be issued in January 1992. Although the FDA is not obligated to abide by the panel's recommendations, the agency usually follows such recommendations.
 McGhan said the company will continue to work with the FDA to further support McGhan Medical's PMA submittal. The chairman said he was confident of a positive outcome, but noted there were no guarantees that approval would be issued.
 INAMED Corporation is a medical device company with 13 operating subsidiaries in the United States and Europe. The company develops, manufactures and markets medical devices for the plastic and reconstructive, bariatric and general surgery markets. The company reported sales of over $35.7 million for the year ending Dec. 31, 1990, a 37 percent increase over sales during 1989.
 INAMED CORPORATION
 Statement of Operations
 Period ended Three Months Nine Months
 Sept. 30 1991 1990 1991 1990
 Sales $9,242,869 $8,778,799 $31,182,890 $26,621,837
 Net income $ 90,986 $ 320,504 $ 954,489 $ 976,540
 Profit per share $.01 $.04 $.12 $.12
 Weighted average
 shares outstanding 8,155,954 7,959,556 8,068,935 7,971,610
 -0- 11/20/91
 /CONTACT: Donald K. McGhan, chairman of INAMED, 805-684-6277; or Jimmy Caplan of Market Makers, 805-569-6919, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, both for INAMED/
 (IMDC) CO: INAMED Corporation ST: California IN: MTC SU: ERN GK -- NY006 -- 5238 11/20/91 08:28 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:544
Previous Article:WHITBREAD PLC: RESILIENCE IN THE FACE OF RECESSION
Next Article:TIMM F. CRULL NAMED TO HEAD NESTLE'S NORTH AMERICAN OPERATIONS
Topics:


Related Articles
INAMED CORP. REPORTS RESULTS
INAMED NAMES FARNEY CEO
INAMED REPORTS RECORD SECOND QUARTER AND SIX-MONTH SALES AND PROFITS
INAMED REPORTS RECORD NINE MONTH SALES AND PROFITS
INAMED REPORTS RECORD SECOND QUARTER AND SIX MONTH PROFITS
INAMED REPORTS RECORD THIRD QUARTER RESULTS
INAMED CORP. REPORTS RECORD SALES FOR 1993; COMPANY TO TAKE LITIGATION SETTLEMENT ADJUSTMENT OF $9.15 MILLION
INAMED CORP. REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
Inamed Corporation Licenses Rights for Product Applications From Advanced Tissue Sciences.
INAMED REPORTS TOTAL SALES FOR 2ND QTR HIGHEST EVER.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters